Other Grants & Awards Programs

Lymphatics in Health and Disease in the Digestive System (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

NIDDK intends to commit $1,000,000 in FY 2018 to fund up to 3 R01 awards. Application budgets are limited to $250,000 direct costs per year exclusive of subcontracts F&A. The maximum project period is 5 years.

For application instructions and more information, please visit https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-021.html.

Open Date (Earliest Submission Date) - January 21, 2019

Letter of Intent Due Date(s) - January 21, 2019

Application Due Date(s) - February 21, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More >
Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R21-Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Purpose: Attaining effective therapies for rare diseases is challenging due to their low prevalence resulting in fewer patients, clinicians, researchers, and resources compared to common diseases. This leads to gaps in our understanding of a rare disease’s natural history, and a dearth of suitable biomarkers or clinical outcome measures, or of other components needed to design, conduct, and interpret rigorous clinical trials.

The Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences (NCATS) along with the Institutes and Centers (ICs) listed in Part I at the National Institutes of Health (NIH) intend to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

For application instructions and more information, please visit https://grants.nih.gov/grants/guide/pa-files/PAR-18-953.html.

Open Date (Earliest Submission Date) - December 07, 2018
Letter of Intent Due Date(s) - 30 days prior to receipt date
Application Due Date(s) - January 7, 2019, June 10, 2019, October 24, 2019, June 8, 2020, October 26, 2020, June 7, 2021, October 25, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More >
Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R03-Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Purpose: Attaining effective therapies for rare diseases is challenging due to their low prevalence resulting in fewer patients, clinicians, researchers, and resources compared to common diseases. This leads to gaps in our understanding of a rare disease’s natural history, and a dearth of suitable biomarkers or clinical outcome measures, or of other components needed to design, conduct, and interpret rigorous clinical trials.

The Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences (NCATS) along with the Institutes and Centers (ICs) listed in Part I at the National Institutes of Health (NIH) intend to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

For application instructions and more information, please visit https://grants.nih.gov/grants/guide/pa-files/PAR-18-952.html.

Open Date (Earliest Submission Date) - December 07, 2018
Letter of Intent Due Date(s) - 30 days prior to the application due date
Application Due Date(s) - January 7, 2019, June 10, 2019, October 24, 2019, June 8, 2020, October 26, 2020, June 7, 2021, October 25, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More >
Lymphatic researchers needed for NIH Study Sections

NIH has requested that LE&RN assemble and deliver to NIH a list of lymphatic researchers who are willing to serve on NIH Study Sections. They have identified the following three Study Sections that review lymphatic grant proposals:

* Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.

* Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.

* Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.

If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:

* Name
* Affiliation
* Study Section(s) on which you are willing to serve
* In 50 words or less, your qualifications for each Study Section selected
* Include CV

Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.
Department of Defense (DoD) Peer-Reviewed Medical Research Program

Fiscal Year 2018 (FY18) funding opportunities for the DoD Breast Cancer Research Program (BCRP), and the Peer Reviewed Cancer Research Program (PRCRP) are being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

Researchers looking at the intersection of lymphedema (LE) and lymphatic disease (LD) and cancer treatment should be eligible for these funding opportunities:

Breast Cancer Research Program (BCRP)

- Breakthrough Award Levels 1 and 2
- Breakthrough Award Levels 3 and 4

Peer Reviewed Cancer Research Program (PRCRP)

- Horizon Award (pre-doctoral candidates and post-doctoral fellows award mechanism)

Detailed descriptions of the funding opportunity, evaluation criteria, and submission requirements can be found in the Program Announcements. The Program Announcements can be downloaded at Grants.gov, the CDMRP, and the electronic Biomedical Research Application Portal (eBRAP).

All CDMRP funding opportunities, both recently and previously released, are available at the CDMRP.

Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on Grants.gov by performing a basic search using CFDA Number 12.420.

Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.
Learn More >
Online Partnership to Accelerate Research

OnPAR (Online Partnership to Accelerate Research) is a matchmaking platform where applicants and non-government funders come together. Leidos Health’s Life Sciences has partnered with NIH and other funding organizations to accelerate the biomedical research and development enterprise by matching high-scoring unfunded applications with private biomedical foundations and/or industries seeking to fund promising research via OnPAR (e.g., for NIH these would be applications within the 30th percentile but are beyond the funding cutoff).

OnPAR has member organizations and matches the unfunded applications with the funding organization. For more information, please visit https://onpar.leidosweb.com/.
Learn More >
Patient-Centered Outcomes Research Institute

PCORI funds research into conditions that affect large numbers of people across a range of populations; conditions that place a heavy burden on individuals, families, specific populations, and society; and rare diseases, which are difficult to study. PCORI funds research through organizations and not individuals. Find out more at www.pcori.org/content/what-who-we-fund.
Learn More >